Inclusion Criteria:  age >18 years; all patients with a clinical indication to Percutaneous Coronary Intervention (PCI) (stable coronary artery disease or acute coronary syndromes); native coronary artery lesion in a vessel with diameter >2.0 mm and ≦3.0 mm at visual estimation; maximum lesion length: 40 mm. informed consent to participate in the study.  Exclusion Criteria:  patients with known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, prasugrel, ticagrelor, sirolimus or contrast media, which cannot be adequately pre-medicated; patients participating in another clinical study; subject is a woman who is pregnant or nursing (pregnancy test, either urine or blood test must be performed within 7 days prior to the index procedure in woman of child-bearing potential, and must not commit to initiating a pregnancy for 12 weeks after implantation, using effective contraception); creatinine clearance <30 ml/min; left ventricular ejection fraction <30%; life expectancy <12 months; ST-elevation myocardial infarction in the previous 48 hours; visible thrombus at lesion site; culprit lesion stenosis >99% and/or Thrombolysis In Myocardial Infarction (TIMI) flow <2; target lesion/vessel with any of the following characteristics: concomitant PCI at the same vessel with any device (vessels are considered: left anterior descending, circumflex or right coronary artery); pre-dilatation of the target lesion not performed or not successful (residual stenosis >30%); severe calcification of the target vessel, at lesion site but also proximally; highly tortuous vessel which could impair device delivery to the lesion site following Investigator's judgement; previous stent implantation at target vessel (left anterior descending artery; circumflex artery; right coronary artery); bifurcation lesion where side branch treatment is anticipated; left main stem stenosis >50%; target lesion is in left main stem